Clinical Trials Search at Vanderbilt-Ingram Cancer Center
Trial of Brigatinib After Treatment With Next-Generation ALK Inhibitors
Multiple Cancer Types
The purpose of this study is to evaluate the safety and effectiveness of this investigational drug, brigatinib (AP261136) in patients with advanced non-small cell lung cancer Non-small cell lung cancer (NSCLC) who have had first-line treatment for their cancer and it still got worse, even after, or while taking drugs called ALK inhibitors, or anti-cancer drugs that act on tumors. Some examples of these anti-cancer drugs are: KEYTRUDA® or ALECENSA®).
Lung,
Non Small Cell
II
Horn, Leora
NCT02706626
VICCTHO1736
